{
    "id": 9718,
    "fullName": "CD74 - ROS1",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CD74-ROS1 results from the fusion of CD74 and ROS1, and leads to constitutive phosphorylation of Ros1 and transformation of cells in culture (PMID: 22659450). CD74-ROS1 fusion is associated with non-small cell lung cancer (PMID: 22215748).",
            "references": [
                {
                    "id": 3337,
                    "pubMedId": 22659450,
                    "title": "The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22659450"
                },
                {
                    "id": 3338,
                    "pubMedId": 22215748,
                    "title": "ROS1 rearrangements define a unique molecular class of lung cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22215748"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 972,
        "geneSymbol": "CD74",
        "terms": [
            "CD74",
            "DHLAG",
            "HLADG",
            "Ia-GAMMA",
            "II",
            "p33"
        ]
    },
    "variant": "CD74 - ROS1",
    "createDate": "07/28/2015",
    "updateDate": "03/01/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 6098,
                "geneSymbol": "ROS1",
                "terms": [
                    "ROS1",
                    "c-ros-1",
                    "MCF3",
                    "ROS"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 2615,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing CD74-ROS1 in culture (PMID: 22659450).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3337,
                    "pubMedId": 22659450,
                    "title": "The oncogenic lung cancer fusion kinase CD74-ROS activates a novel invasiveness pathway through E-Syt1 phosphorylation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22659450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2617,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17684,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Xalkori (crizotinib) resulted an objective response rate (ORR) of 70% (21/30; all partial responses) and median progression-free survival (PFS) of 20 months in non-small cell lung cancer patients with ROS1 rearrangements, and patients harboring a CD74-ROS1 fusion showed a nonsignificant trend toward higher PFS and ORR compared to patients with other ROS1 fusions (PMID: 30978502; NCT02183870).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15732,
                    "pubMedId": 30978502,
                    "title": "Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30978502"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9730,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Rozlytrek (entrectinib) inhibited ROS1 phosphorylation, downstream ERK activation, and growth of transformed cells expressing CD74-ROS1 in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16874,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring CD74-ROS1 (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1319).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14995,
                    "pubMedId": null,
                    "title": "Repotrectinib, a new generation ROS1 inhibitor, is highly potent against fusion ROS1s and emerging resistance mutations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20632,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model with lung cancer harboring CD74-ROS1 was sensitive to DS6051b, demonstrating tumor growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2671,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lestaurtinib suppressed the growth of cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 793,
                "therapyName": "Lestaurtinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10493,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, combined analysis of 2 Phase I trials showed Rozlytrek (entrectinib) treatment to result in a complete response in a patient with non-small cell lung carcinoma harboring CD74-ROS1 fusion that was treatment-naive (PMID: 28183697).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 8566,
                    "pubMedId": 28183697,
                    "title": "Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28183697"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6400,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a patient with CD74-ROS1 positive lung adenocarcinoma as the major tumor clonal population responded within 4 weeks and achieved a near complete response at 12 weeks while being treated with Cabometyx (cabozantinib) and has remained on therapy for at least 8 months (PMID: 26673800).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 6410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cabometyx (cabozantinib) inhibited Ros1 phosphorylation, downstream signaling and growth of transformed cells expressing CD74-ROS1 in culture (PMID: 26673800).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2633,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2616,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3879,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, two patients with lung adenocarcinoma tumors harboring CD74-ROS1 responded to Xalkori (crizotinib) treatment prior to the formation of resistance mutations (PMID: 25688157).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6397,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with CD74-ROS1 positive lung adenocarcinoma achieved a durable partial response (64% reduction in disease burden via RECIST criteria) while being treated with Xalkori (crizotinib), but at 26 months had developed widespread resistance to the therapy due to the emergence of resistance mutations (PMID: 26673800).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16321,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited growth of transformed cells expressing CD74-ROS1 in culture, led to tumor regression in cell line xenograft models (PMID: 30093503).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2670,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells overexpressing CD74-ROS1 in culture (PMID: 24218589).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3476,
                    "pubMedId": 24218589,
                    "title": "Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24218589"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2637,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alecensa (alectinib) had no effect on Ros1 kinase activity, downstream signaling, and growth suppression of transformed cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20622,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing TPM3-NTRK1 and patient-derived cells harboring TPM3-NTRK1 demonstrated cell growth inhibition when treated with DS6051b in culture (PMID: 31399568).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2634,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ASP3026 inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 643,
                "therapyName": "ASP3026",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9727,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited ROS1 phosphorylation, downstream ERK activation, and growth of transformed cells expressing CD74-ROS1 in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 9688,
                "profileName": "CD74 - ROS1"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20648,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 and ROS1 G2032R were sensitive to treatment with DS6051b, demonstrating cell growth inhibition in culture and tumor growth inhibition in mouse models (PMID: 31399568).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16333,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring an CD74-ROS1 fusion developed progressive disease after initial response to Xalkori (crizotinib), and ROS1 G2032R was identified in the post-progression biopsy (PMID: 30093503).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6672,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ROS1 G2032R in the context of CD74-ROS1 was associated with acquired resistance to Xalkori (crizotinib) in a non-small cell lung cancer patient (PMID: 23724914).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 901,
                    "pubMedId": 23724914,
                    "title": "Acquired resistance to crizotinib from a mutation in CD74-ROS1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23724914"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2635,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived NSCLC cells harboring ROS1 G2032R in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3878,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib)-resistant tumor tissues collected from two lung adenocarcinoma patients expressed ROS1 G2032R in the context of a CD74-ROS1 fusion (PMID: 25688157).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13488,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 G2032R in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2672,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells overexpressing ROS1 G2032R in the context of CD74-ROS1 in culture (PMID: 24218589).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3476,
                    "pubMedId": 24218589,
                    "title": "Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24218589"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing CD74-ROS1 with a ROS1 G2032R mutation demonstrated a decreased response to Rozlytrek (entrectinib) in culture compared to cells expressing wild-type CD74-ROS1 (PMID: 27370605).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13487,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 G2032R in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9729,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing CD74-ROS1 with a ROS1 G2032R mutation demonstrated a decreased response to Lorlatinib (PF-06463922) compared to cells expressing CD74-ROS1 with wild-type ROS1, in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing CD74-ROS1 G2032R were resistant to TAE684-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2673,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 suppressed the growth of cells expressing CD74-ROS1 G2032R in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 2636,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 G2032R in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743, PMID: 23724914).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 901,
                    "pubMedId": 23724914,
                    "title": "Acquired resistance to crizotinib from a mutation in CD74-ROS1.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23724914"
                },
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3880,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 G2032R in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2652,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of transformed cells expressing ROS1 G2032R in the context of CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16334,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Repotrectinib (TPX-0005) treatment resulted in partial response lasted for 7.4 months in a patient with non-small cell lung cancer harboring ROS1 G2032R in the context of CD74-ROS1, and the patient remained on treatment for over 12 months (PMID: 30093503; NCT03093116).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ROS1 G2032R in the context of CD74-ROS1 in culture, resulted in tumor regression in cell line xenograft models (PMID: 30093503).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8338,
                    "pubMedId": null,
                    "title": "TPX-0005, a novel ALK/ROS1/TRK inhibitor, effectively inhibited a broad spectrum of mutations including solvent front ALK G1202R, ROS1 G2032R and TRKA G595R mutants",
                    "url": "http://www.ejcancer.com/article/S0959-8049%2816%2932675-2/abstract"
                },
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited Ros1 kinase activity, decreased downstream signaling, and suppressed the growth of non-small cell lung carcinoma cells harboring ROS1 G2032R in the context of CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2666,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 G2032R in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9816,
                "profileName": "CD74 - ROS1 ROS1 G2032R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2664,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 with ROS1 E1990G and M2128V were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9818,
                "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2663,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 E1990G and M2128V in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9818,
                "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2665,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 L1951R in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9845,
                "profileName": "CD74 - ROS1 ROS1 L1951R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20645,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 and ROS1 L1951R were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 9845,
                "profileName": "CD74 - ROS1 ROS1 L1951R"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2662,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 with ROS1 L1951R were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9845,
                "profileName": "CD74 - ROS1 ROS1 L1951R"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2661,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 L1951R in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9845,
                "profileName": "CD74 - ROS1 ROS1 L1951R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9728,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorlatinib (PF-06463922) inhibited ROS1 phosphorylation, downstream ERK activation, and growth of transformed cells expressing ROS1 L2026M in the context of CD74-ROS1 in culture (PMID: 27370605, PMID: 25733882).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                },
                {
                    "id": 13198,
                    "pubMedId": 25733882,
                    "title": "PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25733882"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3889,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 suppressed the growth of cells expressing CD74-ROS1 L2026M in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20647,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 and ROS1 L2026M were sensitive to treatment with DS6051b in culture, demonstrating cell growth inhibition (PMID: 31399568).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2669,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited Ros1 kinase activity and suppressed the growth of transformed cells expressing ROS1 L2026M in the context of CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2668,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited Ros1 kinase activity and suppressed the growth of cells expressing ROS1 L2026M in the context of CD74-ROS1 in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9733,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing CD74-ROS1 with a ROS1 L2026M mutation demonstrated a decreased response to Rozlytrek (entrectinib) in culture compared to cells expressing wild-type CD74-ROS1 (PMID: 27370605).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 3884,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) suppressed the growth of transformed cells expressing ROS1 L2026M in the context of CD74-ROS1 in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9715,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) inhibited ROS1 phosphorylation and downstream ERK activation and growth of transformed cells expressing CD74-ROS1 L2026M in culture (PMID: 27370605).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7489,
                    "pubMedId": 27370605,
                    "title": "Identification of Existing Drugs That Effectively Target NTRK1 and ROS1 Rearrangements in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27370605"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2667,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 L2026M in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9846,
                "profileName": "CD74 - ROS1 ROS1 L2026M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7341,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 K2003I in the context of CD74-ROS1 were sensitive to Zykadia (ceritinib) in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9847,
                "profileName": "CD74 - ROS1 ROS1 K2003I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 K2003I in the context of CD74-ROS1 were sensitive to Xalkori (crizotinib) in culture (PMID: 25351743).",
            "molecularProfile": {
                "id": 9847,
                "profileName": "CD74 - ROS1 ROS1 K2003I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3339,
                    "pubMedId": 25351743,
                    "title": "Cabozantinib overcomes crizotinib resistance in ROS1 fusion-positive cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25351743"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3883,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells overexpressing ROS1 L2155S in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089)-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16562,
                "profileName": "CD74 - ROS1 ROS1 L2155S"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 L2155S in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16562,
                "profileName": "CD74 - ROS1 ROS1 L2155S"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3886,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74 - ROS1 L2155S were resistant to TAE684-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16562,
                "profileName": "CD74 - ROS1 ROS1 L2155S"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3890,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE684 suppressed the growth of transformed cells expressing ROS1 G2101A in the context of CD74-ROS1 in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16564,
                "profileName": "CD74 - ROS1 ROS1 G2101A"
            },
            "therapy": {
                "id": 2386,
                "therapyName": "TAE684",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3885,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) suppressed the growth of transformed cells expressing ROS1 G2101A in the context of CD74-ROS1 in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16564,
                "profileName": "CD74 - ROS1 ROS1 G2101A"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3882,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing ROS1 G2101A in the context of CD74-ROS1 were resistant to Xalkori (crizotinib)-mediated growth inhibition in culture (PMID: 25688157).",
            "molecularProfile": {
                "id": 16564,
                "profileName": "CD74 - ROS1 ROS1 G2101A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4265,
                    "pubMedId": 25688157,
                    "title": "Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25688157"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Repotrectinib (TPX-0005) inhibited proliferation of transformed cells expressing ROS1 D2033N in the context of CD74-ROS1 in culture (PMID: 30093503).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 3950,
                "therapyName": "Repotrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12439,
                    "pubMedId": 30093503,
                    "title": "Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30093503"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cabometyx (cabozantinib) inhibited Ros1 phosphorylation, downstream signaling and growth of transformed cells expressing CD74-ROS1 and ROS1 D2033N in culture (PMID: 26673800).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6398,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with CD74-ROS1 positive lung adenocarcinoma with an acquired ROS1 D2033N mutation in 15-20% of the tumor clonal population and in metastases was resistant to Xalkori (crizotinib) therapy (PMID: 26673800).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing CD74-ROS1 and ROS1 D2033N were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 26673800).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20649,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CD74-ROS1 and ROS1 D2033N were resistant to treatment with DS6051b in culture (PMID: 31399568).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 4343,
                "therapyName": "DS6051b",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 17972,
                    "pubMedId": 31399568,
                    "title": "The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31399568"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6399,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with CD74-ROS1 positive lung adenocarcinoma with an acquired ROS1 D2033N mutation in 15-20% of the tumor clonal population and in metastases responded within 4 weeks and achieved a near complete response at 12 weeks while being treated with Cabometyx (cabozantinib), and has remained on therapy for at least 8 months (PMID: 26673800).",
            "molecularProfile": {
                "id": 23290,
                "profileName": "CD74 - ROS1 ROS1 D2033N"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5546,
                    "pubMedId": 26673800,
                    "title": "A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1-Rearranged Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26673800"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13315,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13304,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 demonstrated decreased response to Cometriq (Cabometyx, cabozantinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13316,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13313,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13314,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13310,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 M2134I in the context of CD74-ROS1 demonstrated decreased response to Foretinib (GSK1363089) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29085,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13486,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13485,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13484,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13483,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13482,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13481,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 M2134I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29086,
                "profileName": "CD74 - ROS1 ROS1 M2134I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13470,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13472,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13473,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 D2113N in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29087,
                "profileName": "CD74 - ROS1 ROS1 D2113N"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13322,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13317,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13318,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13326,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13321,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13324,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113N in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29088,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13476,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13480,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13478,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13477,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13475,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 D2113G in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29089,
                "profileName": "CD74 - ROS1 ROS1 D2113G"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13333,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13332,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to Zykadia (ceritinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13329,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13328,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13331,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13330,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 D2113G in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29090,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13466,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13464,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13468,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13467,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13465,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13463,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 V2098I in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29091,
                "profileName": "CD74 - ROS1 ROS1 V2098I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13339,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13335,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 demonstrated decreased response to Foretinib (GSK1363089) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13334,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 demonstrated decreased response to Cometriq (Cabometyx, cabozantinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13336,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13338,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13337,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2098I in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29092,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13460,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13457,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13458,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13459,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13461,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 V2089M in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29093,
                "profileName": "CD74 - ROS1 ROS1 V2089M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13342,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Alunbrig (brigatinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13346,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13340,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Cometriq (Cabometyx, cabozantinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13345,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13343,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13347,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 V2089M in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29094,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13449,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13445,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13448,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13444,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13447,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13446,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 F2075V in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29095,
                "profileName": "CD74 - ROS1 ROS1 F2075V"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13354,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13353,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13351,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13350,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13352,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13349,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075V in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29096,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13455,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13454,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13456,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13453,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13451,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13452,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 F2075C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29097,
                "profileName": "CD74 - ROS1 ROS1 F2075C"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13358,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13355,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13357,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13359,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13356,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13360,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2075C in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29098,
                "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13440,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13431,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13442,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13435,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13443,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13438,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 E2020K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29099,
                "profileName": "CD74 - ROS1 ROS1 E2020K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13365,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13363,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13362,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13366,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to Zykadia (ceritinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13367,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13364,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 E2020K in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29100,
                "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13417,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13419,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13421,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13416,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13420,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13418,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 F2004C in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29101,
                "profileName": "CD74 - ROS1 ROS1 F2004C"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13373,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 were resistant to Alunbrig (brigatinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13378,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 demonstrated decreased response to Zykadia (ceritinib) compared to cells expressing CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13370,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 were resistant to Foretinib (GSK1363089) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13369,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 were resistant to Cometriq (Cabometyx, cabozantinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13377,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 were resistant to AZD3463 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13371,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing both ROS1 G2032R and ROS1 F2004C in the context of CD74-ROS1 were resistant to Xalkori (crizotinib) in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29102,
                "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13414,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD3463 inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 1586,
                "therapyName": "AZD3463",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13409,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (Cabometyx, cabozantinib) inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13412,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13410,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Foretinib (GSK1363089) inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 743,
                "therapyName": "Foretinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13411,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13413,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing ROS1 E1974K in the context of CD74-ROS1 in culture (PMID: 26372962).",
            "molecularProfile": {
                "id": 29119,
                "profileName": "CD74 - ROS1 ROS1 E1974K"
            },
            "therapy": {
                "id": 789,
                "therapyName": "Ceritinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4022,
                    "pubMedId": 26372962,
                    "title": "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26372962"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14550,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung carcinoma patient harboring CD74-ROS1 progressed on treatment with Xalkori (crizotinib), and cells derived from this patient showed resistance to Xalkori (crizotinib) in culture, and further analysis showed ERBB2 (HER2) expression and phosphorylation (PMID: 29636358).",
            "molecularProfile": {
                "id": 30192,
                "profileName": "CD74 - ROS1 ERBB2 pos"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14551,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma patient-derived cells harboring CD74-ROS1 and expressing ERBB2 (HER2) showed treating the cells with Gilotrif (afatinib) inhibited AKT and ERK1/2 signaling, and partially restored the sensitivity of Xalkori (crizotinib) treatment in culture, and further demonstrated ERBB2 (HER2) phosphorylation (PMID: 29636358).",
            "molecularProfile": {
                "id": 30192,
                "profileName": "CD74 - ROS1 ERBB2 pos"
            },
            "therapy": {
                "id": 3378,
                "therapyName": "Afatinib + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11739,
                    "pubMedId": 29636358,
                    "title": "Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29636358"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18184,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 and ROS1 F2004V was resistant to treatment with Alunbrig (brigatinib) (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18185,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 and ROS1 F2004V was sensitive to treatment with Lorbrena (lorlatinib), demonstrating disease control for 6 months after treatment and a systemic response (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18183,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring CD74-ROS1 developed progression while being treated with Rozlytrek (entrectinib) and through cell-free DNA analysis, was found to have acquired ROS1 F2004V (JCO Precision Oncology, Jun 2019).",
            "molecularProfile": {
                "id": 33045,
                "profileName": "CD74 - ROS1 ROS1 F2004V"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16046,
                    "pubMedId": null,
                    "title": "Dramatic Response to Lorlatinib in a Patient With CD74-ROS1-Positive Lung Adenocarcinoma With Acquired F2004V Mutation",
                    "url": "https://ascopubs.org/doi/full/10.1200/PO.19.00013"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 9688,
            "profileName": "CD74 - ROS1",
            "profileTreatmentApproaches": [
                {
                    "id": 6483,
                    "name": "ROS1 Inhibitor",
                    "profileName": "CD74 - ROS1"
                }
            ]
        },
        {
            "id": 9816,
            "profileName": "CD74 - ROS1 ROS1 G2032R",
            "profileTreatmentApproaches": [
                {
                    "id": 16965,
                    "name": "Foretinib",
                    "profileName": "CD74 - ROS1 ROS1 G2032R"
                },
                {
                    "id": 16966,
                    "name": "Cabozantinib",
                    "profileName": "CD74 - ROS1 ROS1 G2032R"
                },
                {
                    "id": 16964,
                    "name": "Repotrectinib",
                    "profileName": "CD74 - ROS1 ROS1 G2032R"
                }
            ]
        },
        {
            "id": 9818,
            "profileName": "CD74 - ROS1 ROS1 E1990G ROS1 M2128V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9845,
            "profileName": "CD74 - ROS1 ROS1 L1951R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 9846,
            "profileName": "CD74 - ROS1 ROS1 L2026M",
            "profileTreatmentApproaches": [
                {
                    "id": 16951,
                    "name": "Foretinib",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                },
                {
                    "id": 16952,
                    "name": "Ceritinib",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                },
                {
                    "id": 16954,
                    "name": "TAE684",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                },
                {
                    "id": 16953,
                    "name": "Brigatinib",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                },
                {
                    "id": 16955,
                    "name": "Lorlatinib",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                },
                {
                    "id": 16950,
                    "name": "Cabozantinib",
                    "profileName": "CD74 - ROS1 ROS1 L2026M"
                }
            ]
        },
        {
            "id": 9847,
            "profileName": "CD74 - ROS1 ROS1 K2003I",
            "profileTreatmentApproaches": [
                {
                    "id": 16956,
                    "name": "Ceritinib",
                    "profileName": "CD74 - ROS1 ROS1 K2003I"
                },
                {
                    "id": 16957,
                    "name": "Crizotinib",
                    "profileName": "CD74 - ROS1 ROS1 K2003I"
                }
            ]
        },
        {
            "id": 9886,
            "profileName": "CD74 - ROS1 ROS1 L1982F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16562,
            "profileName": "CD74 - ROS1 ROS1 L2155S",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 16564,
            "profileName": "CD74 - ROS1 ROS1 G2101A",
            "profileTreatmentApproaches": [
                {
                    "id": 16963,
                    "name": "Foretinib",
                    "profileName": "CD74 - ROS1 ROS1 G2101A"
                },
                {
                    "id": 16962,
                    "name": "TAE684",
                    "profileName": "CD74 - ROS1 ROS1 G2101A"
                }
            ]
        },
        {
            "id": 23290,
            "profileName": "CD74 - ROS1 ROS1 D2033N",
            "profileTreatmentApproaches": [
                {
                    "id": 16967,
                    "name": "Cabozantinib",
                    "profileName": "CD74 - ROS1 ROS1 D2033N"
                }
            ]
        },
        {
            "id": 29085,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 M2134I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29086,
            "profileName": "CD74 - ROS1 ROS1 M2134I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29087,
            "profileName": "CD74 - ROS1 ROS1 D2113N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29088,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29089,
            "profileName": "CD74 - ROS1 ROS1 D2113G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29090,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 D2113G",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29091,
            "profileName": "CD74 - ROS1 ROS1 V2098I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29092,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2098I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29093,
            "profileName": "CD74 - ROS1 ROS1 V2089M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29094,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 V2089M",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29095,
            "profileName": "CD74 - ROS1 ROS1 F2075V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29096,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29097,
            "profileName": "CD74 - ROS1 ROS1 F2075C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29098,
            "profileName": "CD74 - ROS1 ROS1 G2032R ROS1 F2075C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29099,
            "profileName": "CD74 - ROS1 ROS1 E2020K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29100,
            "profileName": "CD74 - ROS1 ROS1 E2020K ROS1 G2032R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29101,
            "profileName": "CD74 - ROS1 ROS1 F2004C",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29102,
            "profileName": "CD74 - ROS1 ROS1 F2004C ROS1 G2032R",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29119,
            "profileName": "CD74 - ROS1 ROS1 E1974K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30192,
            "profileName": "CD74 - ROS1 ERBB2 pos",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33045,
            "profileName": "CD74 - ROS1 ROS1 F2004V",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35269,
            "profileName": "CD74 - ROS1 ROS1 S1986F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}